

# Avaniyapuram Kannan Murugan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3878278/publications.pdf>

Version: 2024-02-01

58  
papers

3,759  
citations

159358

30  
h-index

138251

58  
g-index

62  
all docs

62  
docs citations

62  
times ranked

5024  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 2718-2726.	0.8	595
2	Highly prevalent <i>TERT</i> promoter mutations in aggressive thyroid cancers. <i>Endocrine-Related Cancer</i> , 2013, 20, 603-610.	1.6	500
3	mTOR: Role in cancer, metastasis and drug resistance. <i>Seminars in Cancer Biology</i> , 2019, 59, 92-111.	4.3	299
4	<i>TERT</i> Promoter Mutations and Their Association with <i>BRAF</i> V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1130-E1136.	1.8	262
5	Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the <i>ALK</i> Gene. <i>Cancer Research</i> , 2011, 71, 4403-4411.	0.4	190
6	Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 555-559.	1.0	122
7	Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. <i>Endocrine-Related Cancer</i> , 2018, 25, R59-R82.	1.6	108
8	Ras oncogenes in oral cancer: The past 20 years. <i>Oral Oncology</i> , 2012, 48, 383-392.	0.8	101
9	RAS mutations in human cancers: Roles in precision medicine. <i>Seminars in Cancer Biology</i> , 2019, 59, 23-35.	4.3	85
10	Histone deacetylation of NIS promoter underlies <i>BRAF</i> V600E-promoted NIS silencing in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 161-173.	1.6	83
11	Identification of <i>RASAL1</i> as a Major Tumor Suppressor Gene in Thyroid Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1617-1627.	3.0	81
12	APOBEC: A molecular driver in cervical cancer pathogenesis. <i>Cancer Letters</i> , 2021, 496, 104-116.	3.2	79
13	MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. <i>Cell Cycle</i> , 2009, 8, 2122-2124.	1.3	73
14	<i>TERT</i> Promoter Mutations in Thyroid Cancer. <i>Hormones and Cancer</i> , 2016, 7, 165-177.	4.9	62
15	Genetic deregulation of the <i>PIK3CA</i> oncogene in oral cancer. <i>Cancer Letters</i> , 2013, 338, 193-203.	3.2	59
16	Long non-coding RNA <i>CCAT1</i> is overexpressed in oral squamous cell carcinomas and predicts poor prognosis. <i>Biomedical Reports</i> , 2017, 6, 455-462.	0.9	58
17	Kirsten Ras* oncogene: Significance of its discovery in human cancer research. <i>Oncotarget</i> , 2016, 7, 46717-46733.	0.8	57
18	Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 649-657.	0.8	55

#	ARTICLE	IF	CITATIONS
19	LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors. <i>Scientific Reports</i> , 2018, 8, 7018.	1.6	55
20	Single Point Mutations in Pediatric Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 189-196.	2.4	54
21	Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 1796.	1.6	51
22	Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. <i>International Journal of Oncology</i> , 2008, 32, 101-111.	1.4	51
23	Comprehensive analysis of aberrantly expressed lncRNAs and construction of ceRNA network in gastric cancer. <i>Oncotarget</i> , 2018, 9, 18386-18399.	0.8	43
24	TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. <i>Endocrine-Related Cancer</i> , 2015, 22, 901-908.	1.6	42
25	Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*. <i>Journal of Biological Chemistry</i> , 2013, 288, 6511-6521.	1.6	40
26	Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. <i>International Journal of Oncology</i> , 2008, , .	1.4	36
27	SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves's disease. <i>Endocrine</i> , 2021, 73, 243-254.	1.1	36
28	SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6191-6221.	1.6	35
29	Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer. <i>Oral Oncology</i> , 2009, 45, e161-e166.	0.8	33
30	Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers. <i>Endocrine Pathology</i> , 2011, 22, 97-102.	5.2	33
31	HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population. <i>Thyroid</i> , 2016, 26, 667-671.	2.4	33
32	TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. <i>Tumor Biology</i> , 2016, 37, 7907-7913.	0.8	32
33	Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 235-241.	2.4	31
34	Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 103-110.	1.8	28
35	Identification and characterization of two novel oncogenic mTOR mutations. <i>Oncogene</i> , 2019, 38, 5211-5226.	2.6	24
36	MicroRNAs: Modulators of the Ras Oncogenes in Oral Cancer. <i>Journal of Cellular Physiology</i> , 2016, 231, 1424-1431.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. Journal of Translational Medicine, 2016, 14, 204.	1.8	19
38	Mutational analysis of rare subtypes of congenital adrenal hyperplasia in a highly inbred population. Molecular and Cellular Endocrinology, 2018, 461, 105-111.	1.6	18
39	Single Nucleotide Polymorphism rs17849071 G/T in the PIK3CA Gene Is Inversely Associated with Follicular Thyroid Cancer and PIK3CA Amplification. PLoS ONE, 2012, 7, e49192.	1.1	17
40	Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. Endocrine, 2019, 63, 94-100.	1.1	14
41	ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila. Oncology Reports, 2008, 20, 957-62.	1.2	13
42	SWAP70 is important for invasive phenotypes of mouse embryo fibroblasts transformed by v-src. IUBMB Life, 2008, 60, 236-240.	1.5	12
43	Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer. Meta Gene, 2015, 6, 69-71.	0.3	12
44	Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options. Biochemical Pharmacology, 2022, 201, 115090.	2.0	12
45	Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncology Letters, 2013, 6, 437-441.	0.8	11
46	ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila. Oncology Reports, 1994, 20, 957.	1.2	9
47	Absence of the frequently reported PIK3CA, CASP8, and NOTCH1 mutations in South Indian oral cancers. Oral Diseases, 2017, 23, 669-673.	1.5	8
48	Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women. Molecular and Clinical Oncology, 2020, 12, 485-494.	0.4	8
49	A high rate of novel CYP11B1 mutations in Saudi Arabia. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 217-224.	1.2	7
50	Single nucleotide polymorphisms in matrix metalloproteinase 2 (MMP2) enhance BRAFV600E mutation-mediated oncogenicity and invasiveness of papillary thyroid cancer cells. Endocrine-Related Cancer, 2021, 28, 273-289.	1.6	5
51	GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer. Oncotarget, 2019, 10, 4107-4124.	0.8	5
52	Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers. Molecular and Clinical Oncology, 2021, 15, 210.	0.4	4
53	Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin. Drug Discoveries and Therapeutics, 2017, 11, 198-205.	0.6	3
54	Linc-ROR genetic variants are associated with the advanced disease in oral squamous cell carcinoma. Archives of Oral Biology, 2022, 139, 105428.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Papillary Thyroid Cancer and a <i>TERT</i> Promotor Mutation-positive Paraganglioma in a Patient With a Germline <i>SDHB</i> Mutation. Journal of the Endocrine Society, 2022, 6, .	0.1	2
56	Familial paraganglioma due to a novel SDHB mutation: familial phenotypic heterogeneity and a potentially novel manifestation. International Journal of Endocrine Oncology, 2019, 6, IJE12.	0.4	1
57	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine Abstracts, 0, , .	0.0	0
58	High incidence of PI3K pathway gene mutations in South Indian cervical cancers. Cancer Genetics, 2022, 264-265, 100-108.	0.2	0